Remestemcel-l for graft vs host disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Trial registered. A trial in people is registered. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 5 May 2026: Trial registered, NCT07568535

The trials

NCT07568535: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Remestemcel-L-rknd Added to Ruxolitinib for Grade III-IV Steroid-Refractory Acute Graft-Versus-Host Disease

State
Not started
Phase
Phase 3
People
180 planned
Started
31 Aug 2026
Primary completion
28 Feb 2028
Arms
Remestemcel-L-rknd
Results
None posted
  1. 5 May 2026: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Trial registered

About the treatment

Kind of treatment: Drug.

Also known as Prochymal, Remestemcel-L-rknd.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.